Antimicrobial Resistance Diagnostics Market, Strategies & Trends By Pathogen And Technology With Executive Guides And Customization 2018 To 2023

  • ID: 4486794
  • Report
  • Region: Global
  • 185 Pages
  • Howe Sound Research
1 of 5
Multiple Diagnostic Technologies Create New Global Race

FEATURED COMPANIES

  • 1928 Diagnostics
  • Atlas Genetics
  • Curetis GmbH
  • Day Zero Diagnostics
  • Great Basin Corporation
  • OpGen
  • MORE

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed.

We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges. All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data. 

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 1928 Diagnostics
  • Atlas Genetics
  • Curetis GmbH
  • Day Zero Diagnostics
  • Great Basin Corporation
  • OpGen
  • MORE

1. Introduction and Market Definition
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Diagnostic Markets - Perspective
1.3.1 U.S. Resistant Microbe Diagnosis Market
1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.3.1 U.S. Medicare Expenditures for Clinical Testing

2. Overview of a Dynamic Market
2.1 Market Players – Roles & Impacts
2.1.1 IVD Manufacturer
2.1.2 Independent Lab Specialized/Esoteric
2.1.3 Independent Lab National/Regional
2.1.4 Independent Analytical Lab
2.1.5 Public National/Regional Lab
2.1.6 Hospital Lab
2.1.7 Physician Lab
2.1.8 Consumer Direct – The Slippery Slope
2.1.9 Audit body .
2.2 Segmentation – Different Approaches
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Structure of Clinical Testing Industry
2.3.1 The Hospital Lab – Share of the Pie
2.3.2 Changing Role for Economies of Scale in Infectious Disease Diagnosis
2.3.3 Physician Office Lab’s – Technology is Changing the Program
2.4 Understanding Antimicrobial Resistance
2.4.1 What is Antimicrobial Resistance (AMR)
2.4.2 Bacteria and Other Microbes
2.4.3 The History of Antibiotics
2.4.4 The Role of Animal Husbandry
2.4.5 The Implications of Horizontal Transfer
2.4.6 The Threat of AMR
2.5 Alternatives to Antibiotics – Implication for Diagnostics

3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC) .
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Diagnostic Technology Development Opportunities
3.2.1  What’s Wrong with Microbiology
3.2.2  The Features Battleground of Infectious Disease Diagnostics
3.2.3  Multiplex vs. POC/Rapid
3.2.4  The Miracle of Genetics
3.2.5  From Multiple Pathogens to All Pathogens – The Next Next Generation
3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing
3.2.7 Markers of Resistance.
3.2.8  What Happens to the Microbiology Lab?
3.4. Antibiotic Resistance Recent Developments
3.4.1 Recent Developments – Importance and How to Use This Section
3.4.2 Importance of These Developments
3.4.3 How to Use This Section
3.4.4 WHO to develop Essential Diagnostics List
3.4.5 Improved Diagnostics Fail to Halt the Rise of Tuberculosis
3.4.6 High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
3.4.7 New solution for diagnosing antibiotic-resistant bacteria
3.4.8 MALDI-TOF – Results in Minutes not Days
3.4.9 CRISPR Tool Used to Uncover Infections
3.4.10 Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
3.4.11 BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
3.4.12 LiDia® BSI Detects Pathogens and Antimicrobial Resistance
3.4.13 New tool can Track Resistant Malaria
3.4.14 Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
3.4.15 Longitude Funds for POC Tests
3.4.16 New test can identify dangerous bacteria with resistance to last-resort antibiotic
3.4.17 bioMérieux receives FDA clearance for expanded pathogen identification capability
3.4.18 OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
3.4.19 Hospital Plumbing Harbors Antibiotic Resistant Bacteria
3.4.20 Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
3.4.21 Curetis Gets Singapore Approval for Pneumonia Test
3.4.22 PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
3.4.23 Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies
3.4.24 Fusion Genomics Developing All Pathogens Diagnostic

4. Key Biotechnology Companies and Their Technology
4.1 Diagnostics
4.1.1 1928 Diagnostics
4.1.2 Sense Biodetection
4.1.3 Fusion Genomics
4.1.4 Day Zero Diagnostics
4.1.5 Inflammatix
4.1.6 Hutman Diagnostics
4.1.8 bioMérieux Diagnostics
4.1.9 Curetis N.V. / Curetis GmbH
4.1.10 Great Basin Corporation
4.1.11 Becton, Dickinson and Company
4.1.12 Roche Diagnostics
4.1.13 Cepheid (now Danaher)
4.1.14 Atlas Genetics
4.1.14 Accelerate Diagnostics
4.1.15 Seimens
4.1.16 Abbott Diagnostics
4.1.17 Thermo Fisher
4.1.18 Bio - Rad
4.1.19  Sysmex
4.1.20 Ortho Clinical
4.1.21 Alere (now Abbott)

5.  Country Market Sizes – North America 2015 to 2023
5.1 United States of America 2015 to 2023
5.1.1 USA by Pathogen
5.1.2 USA by Technology Opportunity
5.2 Canada 2015 to 2023
5.1.1 Canada by Pathogen
5.1.2 Canada by Technology Opportunity

6. Country Markets – Europe 2015 to 2023
6.1 France 2015 to 2023 
6.1.1 France by Pathogen
6.1.2 France by Technology Opportunity
6.2 Germany 2015 to 2023
6.2.1 Germany by Pathogen
6.2.2 Germany by Technology Opportunity
6.3 United Kingdom 2015 to 2023
6.3.1 United Kingdom by Pathogen
6.3.2 United Kingdom by Technology Opportunity
6.4 Spain 2015 to 2023
6.4.1 Spain by Pathogen
6.4.2 Spain by Technology Opportunity
6.5 Italy 2015 to 2023
6.5.1 Italy by Pathogen
6.5.2 Italy by Technology Opportunity
6.6 Russia 2015 to 2023
6.6.1 Russia by Pathogen
6.6.2 Russia by Technology Opportunity
6.7 Remainder of Europe and Former USSR 2015 to 2023
6.7.1 Remainder of Europe and Former USSR by Pathogen
6.7.2 Remainder of Europe and Former USSR by Technology Opportunity

7. Country Markets – Asia Pacific 2015 to 2023
7.1 China 2015 to 2023
7.1.1 China by Pathogen
7.1.2 China by Technology Opportunity
7.2 Japan 2015 to 2023
7.2.1 Japan by Pathogen
7.2.2 Japan by Technology Opportunity
7.3 South Korea 2015 to 2023
7.3.1 South Korea by Pathogen
7.3.2 South Korea by Technology Opportunity
7.4 India 2015 to 2023
7.4.1 India by Pathogen
7.4.2 India by Technology Opportunity
7.5 Australia 2015 to 2023
7.5.1 Australia by Pathogen
7.5.2 Australia by Technology Opportunity
7.6 Remainder of Asia Pacific 2015 to 2023
7.6.1 Remainder of Asia Pacific by Pathogen
7.6.2 Remainder of Asia Pacific by Technology Opportunity

8. Country Markets – Latin America, Africa & The Middle East 2015 to 2023
8.1 Brazil 2015 to 2023 
8.1.1 Brazil by Pathogen
8.1.2 Brazil by Technology Opportunity
8.2 Mexico 2015 to 2023
8.2.1 Mexico by Pathogen
8.2.2 Mexico by Technology Opportunity
8.3 Remainder of Latin America 2015 to 2023
8.3.1 Remainder of Latin America by Pathogen
8.3.2 Remainder of Latin America by Technology Opportunity
8.4 Africa & The Middle East 2015 to 2023
8.4.1 Africa & The Middle East by Pathogen
8.4.2 Africa & The Middle East by Technology Opportunity

9. Global Market Summary 2015 to 2023
9.1 Global Market Summary 2015 to 2023
9.1.1 Global Market Summary by Pathogen
9.1.2 Global Market Summary by Technology Opportunity

10. The Future of AMR

List of Tables
Table 1 USA – Key Resistant Microbe Markets
Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2021 ($Billion)
Table 3  Market Players by Type
Table 4 Clinical Laboratory Departments and Segments
Table 5 Laboratory Management Focus – Different Approaches
Table 6 Key Segmentation Variables Going Forward
Table 7  Known Human Pathogenic Diseases
Table 8 Eight Technologies under development
Table 9 The Key Market Opportunities
Table 10 - Market Potential DRSP Therapeutic
Table 11 - Market Potential DRC Therapeutic
Table 12 – The Long List of Diagnostic Technologies
Table 13  USA by Pathogen
Table 14  USA by Technology Opportunity
Table 15  Canada by Pathogen
Table 16  Canada by Technology Opportunity
Table 17  France By Pathogen
Table 18  France By Technology Opportunity
Table 19  Germany By Pathogen
Table 20  Germany By Technology Opportunity
Table 21  UK By Pathogen
Table 22  UK By Technology Opportunity
Table 23  Spain by Pathogen
Table 24  Spain by Technology Opportunity
Table 25  Italy By Pathogen
Table 26  Italy By Technology Opportunity
Table 27  Russia By Pathogen
Table 28  Russia By Technology Opportunity
Table 29  Remainder of Europe and Former USSR By Pathogen
Table 30  Remainder of Europe and Former USSR By Technology Opportunity
Table 31  China By Pathogen
Table 32  China By Technology Opportunity
Table 33  Japan By Pathogen
Table 34  Japan By Technology Opportunity
Table 35  South Korea By Pathogen
Table 36  South Korea By Technology Opportunity
Table 37  India by Pathogen
Table 38  India by Technology Opportunity
Table 39  Australia By Pathogen
Table 40  Australia By Technology Opportunity
Table 41  Remainder of Asia Pacific By Pathogen
Table 42  Remainder of Asia Pacific By Technology Opportunity
Table 43  Brazil By Pathogen
Table 44  Brazil By Technology Opportunity
Table 45  Mexico By Pathogen
Table 46  Mexico By Technology Opportunity
Table 47  UK By Pathogen
Table 48  Remainder of Latin America By Technology Opportunity
Table 49  Africa & The Middle East by Pathogen
Table 50  Africa & The Middle East by Technology Opportunity
Table 51  Global Market Summary by Pathogen
Table 52  Global Market Summary by Technology Opportunity

Table of Figures
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2021 ($Million)
Figure 2 AMR and Antibiotic Introduction
Figure 3 The Death Toll of AMR

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 1928 Diagnostics
  • Abbott
  • Accelerate Diagnostics
  • Atlas Genetics
  • Becton, Dickinson and Company
  • Bio-Rad
  • bioMérieux Diagnostics
  • Curetis GmbH
  • Curetis N.V.
  • Danaher
  • Day Zero Diagnostics
  • Denka
  • Fusion Genomics
  • Great Basin Corporation
  • Hutman Diagnostics
  • Inflammatix
  • OpGen
  • Ortho Clinical Diagnostics
  • PlexBio
  • Roche Diagnostics
  • Seimens
  • Sense Biodetection
  • Sysmex
  • Thermo Fisher
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll